Publications by authors named "Timothy M Lestingi"

Claim this Profile
R
Role of sorafenib in overcoming resistance of chemotherapy-failure castration-resistant prostate cancer.
Andrew Meyer, Peter Cygan, Kathy Tolzien, Angel G Galvez, Jacob D Bitran, Timothy M Lestingi

Clin Genitourin Cancer· April 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
L
Lenalidomide monotherapy in chemotherapy-naive, castration-resistant prostate cancer patients: final results of a phase II study.
Chadi Nabhan, Anand Patel, Dana Villines, Kathy Tolzien, Susan K Kelby, Timothy M Lestingi

Clin Genitourin Cancer· February 2014

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
A phase II pilot trial investigating the efficacy and activity of single agent granulocyte macrophage colony-stimulating factor as maintenance approach in castration - resistant prostate cancer patients responding to chemotherapy.
Chadi Nabhan, Andrew Meyer, Kathy Tolzien, Jacob D Bitran, Timothy M Lestingi

Avicenna J Med· July 2011

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
E
Erlotinib has moderate single-agent activity in chemotherapy-naïve castration-resistant prostate cancer: final results of a phase II trial.
Chadi Nabhan, Timothy M Lestingi, Angel Galvez, Kathy Tolzien, Susan K Kelby

Urology· September 2009

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis